Randomized, Open-label, Adaptive, Controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Reimmunization With Third Dose of Homologous vs. Heterologous Vaccine Against COVID-19 in Patients Undergoing Solid Organ Transplantation: Liver, Heart, Kidney and Lung.
Latest Information Update: 06 Mar 2023
At a glance
- Drugs Ad26.COV2 S (Primary) ; Elasomeran
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms REIN-TX
- 28 Feb 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Sep 2021 New trial record